NCT01060384 2023-10-04
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
Clinical Trials
5 trialsNCT01294579 2018-08-09
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novartis
Phase 2 Completed
NCT01171378 2018-04-25
CHOP-OR
University of Oxford
Phase 2 Completed
NCT00823719 2013-03-12
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
GlaxoSmithKline
Phase 2 Completed
NCT01108341 2012-08-28
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed